Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 8.943
Filtrar
1.
Anticancer Res ; 40(9): 5229-5235, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32878811

RESUMO

BACKGROUND/AIM: The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclinical antitumor activity. To determine the maximum tolerated dose or a recommended dose, and to delineate the pharmacokinetic profile of LFA102 in Japanese patients, we conducted a phase I study. PATIENTS AND METHODS: LFA102 was intravenously infused every 4 weeks to patients with advanced breast or castration-resistant prostate cancer, and the dose increased from 3 to 40 mg/kg. RESULTS: Fourteen patients were treated, and toxicities were reported in 9 (64%) patients. They were all grade 1 or 2, and the most frequently observed toxicity was nausea (3 patients, 21%). No dose-limiting toxicities were observed. LFA102 did not show antitumor activity as a single agent. CONCLUSION: Treatment with LFA102 was well tolerated.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico , Neoplasias de Próstata Resistentes à Castração/patologia , Idoso , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/farmacocinética , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/efeitos adversos , Antineoplásicos Imunológicos/farmacocinética , Biomarcadores Tumorais , Neoplasias da Mama/etiologia , Neoplasias da Mama/mortalidade , Esquema de Medicação , Monitoramento de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Metástase Neoplásica , Estadiamento de Neoplasias , Neoplasias de Próstata Resistentes à Castração/etiologia , Neoplasias de Próstata Resistentes à Castração/mortalidade , Resultado do Tratamento
2.
Adv Exp Med Biol ; 1252: 195-197, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32816282

RESUMO

Pregnancy and lactation represent the most effective protective elements against breast cancer; counter-intuitively breast cancer incidence shows a small but noticeable increase up to 5 years after delivery. The cumulative effect is however favourable and women show a reduction in breast cancer risk which is proportional to the total duration of lactation and to the number of full-term pregnancies.


Assuntos
Neoplasias da Mama/etiologia , Neoplasias da Mama/prevenção & controle , Lactação , Gravidez , Fatores de Proteção , Aleitamento Materno , Feminino , Humanos , Fatores de Risco
3.
Anticancer Res ; 40(7): 3619-3631, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32620601

RESUMO

MMP-2 and MMP-9 genes have been suggested to play a role in breast cancer. Their functions have been associated with invasion and metastasis of breast cancer; however, their involvement in the development of the disease is not well-established. Herein, we reviewed the literature investigating the association between circulating levels and polymorphisms of MMP-2 and MMP-9 and breast cancer risk. Various studies report conflicting results regarding the relationship of polymorphisms in MMP-2 and MMP-9 and breast cancer risk. Nevertheless, it appears that the T allele in rs243865 and rs2285053 in MMP-2 are associated with reduced risk of breast cancer. In addition, high levels of latent form and low levels of active form of MMP-2 were observed in breast cancer patients compared to controls. For MMP-9, high latent levels and low total levels were found in breast cancer patients compared to controls. Additional studies are needed to comprehend the role of these genes in breast carcinogenesis.


Assuntos
Neoplasias da Mama/etiologia , Neoplasias da Mama/genética , Predisposição Genética para Doença/genética , Metaloproteinase 2 da Matriz/genética , Metaloproteinase 9 da Matriz/genética , Polimorfismo Genético/fisiologia , Alelos , Feminino , Humanos , Risco
4.
Cancer Sci ; 111(9): 3313-3326, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32619077

RESUMO

The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Eligible patients from Japan, Hong Kong, and Singapore were enrolled in this 2-phase study consisting of a dose-escalation phase to determine the maximum-tolerated dose and the recommended Phase II dose of ribociclib plus letrozole, and a dose-expansion phase to evaluate safety and tolerability of ribociclib plus letrozole, fulvestrant, or tamoxifen. An exploratory biomarker analysis evaluating expression of target genes was also conducted. In the dose-escalation phase, the maximum-tolerated/recommended Phase II doses of ribociclib were lower in Japanese patients (300 mg) than in Asian non-Japanese patients (600 mg). Ribociclib plus endocrine therapy at the recommended Phase II dose had a manageable safety profile, with neutropenia and elevated liver transaminases being the most common adverse events leading to dose modifications or discontinuations, and it demonstrated evidence of clinical activity in both Japanese and Asian non-Japanese patients. Preliminary efficacy in Asian populations is similar to that observed in White populations studied in previous ribociclib (MONALEESA) trials. Biomarker analysis demonstrated suppression of pharmacodynamic biomarker gene expression, indicating inhibition of target genes by ribociclib combined with endocrine therapy. Results from the ongoing study support the use of ribociclib in combination with letrozole in Asian non-Japanese patients at the same dose (600 mg) as White patients. In Japanese patients, a lower dose of ribociclib (300 mg) should be considered. Clinicaltrials.gov: NCT02333370.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Idoso , Idoso de 80 Anos ou mais , Aminopiridinas/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Grupo com Ancestrais do Continente Asiático , Biomarcadores , Neoplasias da Mama/etiologia , Neoplasias da Mama/mortalidade , Quinase 4 Dependente de Ciclina/antagonistas & inibidores , Quinase 6 Dependente de Ciclina/antagonistas & inibidores , Feminino , Humanos , Japão , Pessoa de Meia-Idade , Gradação de Tumores , Metástase Neoplásica , Estadiamento de Neoplasias , Inibidores de Proteínas Quinases/administração & dosagem , Purinas/administração & dosagem , Resultado do Tratamento
5.
Plast Reconstr Surg ; 146(1): 30-37, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32590638

RESUMO

BACKGROUND: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has entered the spotlight, as several high-profile media outlets have begun to relay the evolving science to the public. This study aimed to gauge the baseline knowledge and concern regarding BIA-ALCL among adult laywomen within the United States. METHODS: Mechanical Turk was used to survey 500 American women on self-reported demographics, prior experience with breast implants, and 11 questions regarding their knowledge and concern regarding BIA-ALCL. Responses were reviewed for quality control before study inclusion. RESULTS: Overall, 12 percent of respondents had received breast implants and 73 percent knew someone with implants; 13.6 percent of respondents (including 51.7 percent of respondents with implants) had previously heard of BIA-ALCL. After providing information about its risk, 58.4 percent of respondents were still willing to receive a reconstructive implant and 45.8 percent a cosmetic implant; 35.8 percent reported they would be less likely to receive an implant. Of the respondents with breast implants, 66.7 percent reported some degree of concern regarding BIA-ALCL and 35.0 percent are strongly considering removing their implants. Those who had heard of BIA-ALCL consumed information from several sources, predominantly health professionals or media/health care blogs. Different sources of information were not associated with a respondent's degree of concern. CONCLUSIONS: Only a minority of American women have heard of BIA-ALCL and understand its association with breast implants. As plastic surgeons who perform breast reconstruction, we can promote the spread of information through the popular media and health care blogs to address this growing concern, particularly among women with existing breast implants.


Assuntos
Implante Mamário/efeitos adversos , Implantes de Mama/efeitos adversos , Neoplasias da Mama/etiologia , Conhecimentos, Atitudes e Prática em Saúde , Linfoma Anaplásico de Células Grandes/etiologia , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Falha de Prótese/etiologia , Estados Unidos
6.
Gan To Kagaku Ryoho ; 47(3): 540-541, 2020 Mar.
Artigo em Japonês | MEDLINE | ID: mdl-32381942

RESUMO

We present the case of an 88-year-old woman who had undergone breast conserving surgery for left breast cancer 8 years ago.She received postoperative radiotherapy(total dose of 60 G/30 Fr)to the residual breast together with endocrine therapy.She underwent skin biopsy after having had a red skin tumor in the left breast.Angiosarcoma was diagnosed and chemotherapy and radiotherapy were initiated.The patient is alive without recurrence 8 months after chemotherapy.


Assuntos
Neoplasias da Mama/etiologia , Hemangiossarcoma/etiologia , Neoplasias Induzidas por Radiação , Idoso de 80 Anos ou mais , Feminino , Humanos , Recidiva Local de Neoplasia
7.
PLoS One ; 15(5): e0233369, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32433664

RESUMO

INTRODUCTION: Cadmium (Cd) is a heavy metal, which is widespread in the environment and has been hypothesized to be a metalloestrogen and a breast cancer risk factor. Mammographic density (MD) reflects the composition of the breast and was proposed to be used as a surrogate marker for breast cancer. The aim of our study was to investigate association between cadmium concentration in urine and mammographic density. METHODS: A cross-sectional study included 517 women aged 40-60 years who underwent screening mammography in Lódz, Poland. Data were collected through personal interviews and anthropometric measurements. Spot morning urine samples were obtained. The examination of the breasts included both craniocaudal and mediolateral oblique views. Raw data ("for processing") generated by the digital mammography system were analysed using Volpara Imaging Software, The volumetric breast density(%) and fibrograndular tissue volume(cm3) were determined. Cadmium concentration in urine was analysed using the standard ICP-MS method. RESULTS: After adjusting for key confounders including age, BMI, family breast cancer, mammographic device, season of the year of mammography, and age at menarche, an inverse association of Cd and volumetric breast density was found, which was attenuated after further adjustment for smoking. Associations of Cd with dense volume were null. CONCLUSIONS: These findings suggest that Cd is not positively associated with breast density, a strong marker of breast cancer risk, when examined in a cross-sectional fashion.


Assuntos
Densidade da Mama/efeitos dos fármacos , Neoplasias da Mama/etiologia , Cádmio/urina , Mamografia/métodos , Adulto , Neoplasias da Mama/diagnóstico , Cádmio/toxicidade , Estudos Transversais , Feminino , Humanos , Programas de Rastreamento , Pessoa de Meia-Idade , Polônia/epidemiologia , Medição de Risco , Fatores de Risco , Software
8.
Br J Radiol ; 93(1110): 20190869, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32242740

RESUMO

OBJECTIVES: To estimate risk for exposure-induced cancer death (REID), organ-specific risks of exposure-induced cancer death (REIDHT) and associated conversion coefficients (CCREID:KAP=REID/kerma-area product (KAP), CCREIDHT:KAP=REIDHT/KAP) in paediatric cardiac catheterizations using data from radiation dose structured reports (RDSR). A novel risk surveillance tool consisting of age-specific and gender-specific risk reference values (RRVs) related to population cancer risk is suggested. METHODS: The PCXMC v.2.0 code is used together with exposure-related information from RDSR from a cohort of 238 children to assess cancer risks and related conversion coefficients. The KAP corresponding to 1 in 1000 of increased REID is used to define age-specific and gender-specific KAP values to monitor risk in such patient cohorts, here denoted as RRVs. RESULTS: The REID estimates ranged from below 1 up to 300 in 100,000, and the RRVs for the different age groups and gender ranged from 0.77 Gycm2 and 2.1 Gycm2 for neonates (female, male) to 11 Gycm2 and 25 Gycm2 for 15-year-olds (female, male). The CCREID:KAP and CCREIDHT:KAP decreased biexponentially with increased age, being notably higher for female patients. CONCLUSIONS: Prominent risk contributing organs were the lungs and the (female) breast. The concept of age-specific and gender-specific RRVs related to population cancer risk is introduced and is intended to be used as a supporting tool for physicians performing such interventions. ADVANCES IN KNOWLEDGE: Age-related and gender-related conversion coefficients for radiation risk, CCREID:KAP and CCREIDHT:KAP, are introduced and a novel risk surveillance concept, the RRV, is suggested for paediatric cardiac catheterizations.


Assuntos
Fatores Etários , Cateterismo Cardíaco/efeitos adversos , Cardiopatias Congênitas/diagnóstico por imagem , Neoplasias Induzidas por Radiação/mortalidade , Exposição à Radiação/efeitos adversos , Fatores Sexuais , Adolescente , Angiografia , Neoplasias da Mama/etiologia , Neoplasias da Mama/mortalidade , Cateterismo Cardíaco/métodos , Criança , Pré-Escolar , Feminino , Cardiopatias Congênitas/radioterapia , Cardiopatias Congênitas/cirurgia , Humanos , Lactente , Recém-Nascido , Neoplasias Pulmonares/etiologia , Neoplasias Pulmonares/mortalidade , Masculino , Neoplasias Induzidas por Radiação/etiologia , Especificidade de Órgãos/efeitos da radiação , Imagens de Fantasmas , Doses de Radiação , Valores de Referência , Risco
9.
JAMA Netw Open ; 3(4): e203645, 2020 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-32329771

RESUMO

Importance: The role of endogenous progesterone in the development of breast cancer remains largely unexplored to date, primarily owing to assay sensitivity limitations and low progesterone concentrations in postmenopausal women. Recently identified progesterone metabolites may provide insights as experimental data suggest that 5α-dihydroprogesterone (5αP) concentrations reflect cancer-promoting properties and 3α-dihydroprogesterone (3αHP) concentrations reflect cancer-inhibiting properties. Objective: To evaluate the association between circulating progesterone and progesterone metabolite levels and breast cancer risk. Design, Setting, and Participants: Using a sensitive liquid chromatography-tandem mass spectrometry assay, prediagnostic serum levels of progesterone and progesterone metabolites were quantified in a case-cohort study nested within the Breast and Bone Follow-up to the Fracture Intervention Trial (n = 15 595). Participation was limited to women not receiving exogenous hormone therapy at the time of blood sampling (1992-1993). Incident breast cancer cases (n = 405) were diagnosed during 12 follow-up years and a subcohort of 495 postmenopausal women were randomly selected within 10-year age and clinical center strata. Progesterone assays were completed in July 2017; subsequent data analyses were conducted between July 15, 2017, and December 20, 2018. Exposures: Circulating concentrations of pregnenolone, progesterone, and their major metabolites. Main Outcomes and Measures: Development of breast cancer, with hazard ratios (HRs) and 95% CIs was estimated using Cox proportional hazards regression adjusted for key confounders, including estradiol. Evaluation of hormone ratios and effect modification were planned a priori. Results: The present study included 405 incident breast cancer cases and a subcohort of 495 postmenopausal women; the mean (SD) age at the time of the blood draw was 67.2 (6.2) years. Progesterone concentrations were a mean (SD) of 4.6 (1.7) ng/dL. Women with higher circulating progesterone levels were at an increased risk for breast cancer per SD increase in progesterone levels (HR, 1.16; 95% CI, 1.00-1.35; P = .048). The association with progesterone was linear in a 5-knot spline and stronger for invasive breast cancers (n = 267) (HR, 1.24; 95% CI, 1.07-1.43; P = .004). Among women in the lowest quintile (Q1) of circulating estradiol (<6.30 pg/mL) elevated progesterone concentrations were associated with reduced breast cancer risk per SD increase in progesterone levels (HR, 0.38; 95% CI, 0.15-0.95; P = .04) and increased risk among women in higher quintiles of estradiol (Q2-Q5; ≥6.30 pg/mL) (HR, 1.18; 95% CI, 1.04-1.35; P = .01; P = .04 for interaction). Conclusions and Relevance: In this case-cohort study of postmenopausal women, elevated circulating progesterone levels were associated with a 16% increase in the risk of breast cancer. Additional research should be undertaken to assess how postmenopausal breast cancer risk is associated with both endogenous progesterone and progesterone metabolites and their interactions with estradiol.


Assuntos
Neoplasias da Mama/sangue , Progesterona/sangue , Idoso , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/etiologia , Estudos de Casos e Controles , Estradiol/sangue , Feminino , Humanos , Incidência , Estudos Longitudinais , Pessoa de Meia-Idade , Pós-Menopausa , Estudos Prospectivos , Fatores de Risco , Inquéritos e Questionários
10.
Adv Cancer Res ; 146: 57-82, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32241392

RESUMO

Factors such as socioeconomic status, age at menarche and childbearing patterns are components that have been shown to influence mammary gland development and establish breast cancer disparity. Pubertal mammary gland development is selected as the focus of this review, as it is identified as a "window of susceptibility" for breast cancer risk and disparity. Here we recognize non-Hispanic White, African American, and Asian American women as the focus of breast cancer disparity, in conjunction with diets associated with changes in breast cancer risk. Diets consisting of high fat, N-3 polyunsaturated fatty acids, N-6 polyunsaturated fatty acids, as well as obesity and the Western diet have shown to lead to changes in pubertal mammary gland development in mammalian models, therefore increasing the risk of breast cancer and breast cancer disparity. While limited intervention strategies are offered to adolescents to mitigate development changes and breast cancer risk, the prominent solution to closing the disparity among the selected population is to foster lifestyle changes that avoid the deleterious effects of unhealthy diets.


Assuntos
Neoplasias da Mama/etiologia , Mama/crescimento & desenvolvimento , Transformação Celular Neoplásica/patologia , Dieta/efeitos adversos , Suscetibilidade a Doenças , Disparidades em Assistência à Saúde/estatística & dados numéricos , Neoplasias da Mama/patologia , Feminino , Humanos
11.
Chem Biol Interact ; 322: 109060, 2020 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-32171849

RESUMO

BACKGROUND: Individual observational studies have suggested null, weak, linear, and J-shaped associations between alcohol consumption and breast cancer risk. However, observational studies are susceptible to confounders, which can obscure the true impact of an exposure on an outcome. Given the uncertainty regarding the association between alcohol consumption and breast cancer, and the challenges of identifying, measuring, and accounting for all potential confounders, we assessed whether and how authors of observational studies evaluating the impact of alcohol consumption on the risk of breast cancer considered bias when interpreting their main study findings. METHODS: We identified all observational studies included in a recent alcohol-breast cancer meta-analysis. The Abstract and/or Discussion sections were reviewed to determine whether authors considered confounding. RESULTS: Among 101 eligible studies, 73 (72.3%) mentioned confounding explicitly in the Abstract and Discussion sections. There were 33 (32.7%) studies that included statements regarding specific confounders that were not adjusted for in the analyses and 60 (59.4%) studies without any statements about the impact of residual confounding on their main findings. Although none of the studies outlined that their main findings were "likely" to be affected by residual confounding, 25 (24.8%) mentioned a "possible" impact and 16 (15.8%) claimed an "unlikely" impact. Only one (1.0%) article explicitly stated that caution was needed when interpreting their findings due to confounding. CONCLUSION: These results highlight the need for more adequate consideration of the potential impact of residual confounding in observational studies evaluating the impact of alcohol consumption on the risk of breast cancer.


Assuntos
Consumo de Bebidas Alcoólicas , Neoplasias da Mama/etiologia , Neoplasias da Mama/epidemiologia , Bases de Dados Factuais , Feminino , Carga Global da Doença , Humanos , Fatores de Risco
12.
Cir. plást. ibero-latinoam ; 46(1): 25-36, ene.-mar. 2020. tab
Artigo em Espanhol | IBECS | ID: ibc-190855

RESUMO

INTRODUCCIÓN Y OBJETIVO: Desde 1995 en que se publicó la primera notificación que relacionaba el linfoma anaplásico de células grandes al hecho de portar implantes mamarios (LACG-AIM) han transcurrido más de 25 años y han sido publicados cientos de artículos. El presente trabajo tiene como objetivo realizar una revisión sistemática y analítica de los casos publicados, así como sintetizar el conocimiento actual sobre esta entidad y acercarlo al lector de habla hispana. MATERIAL Y MÉTODO: Realizamos una búsqueda sistemática en las bases de datos PubMed, ScienceDirect y SciELO así como en el buscador de Google Académico entre 1995 y octubre de 2019, que pretende revisar las características de los casos recogidos en la literatura en dicho periodo de tiempo. RESULTADOS: El número total de casos recogidos en la bibliografía analizada fue de 122. La información resultó heterogénea y mayoritariamente basada en notificaciones de casos. Cabe destacar la escasez de casos publicados desde países íbero-latinoamericanos. Exponemos los principales datos recogidos relativos a características del linfoma, sintomatología, diagnóstico, patogenia, estudios genéticos, mutaciones, tratamiento, pronóstico y supervivencia. CONCLUSIONES: Aunque el diagnóstico y tratamiento actual del LACG-AIM se encuentran bastante estandarizados, la incidencia real y la etiología de esta entidad necesitan de estudios más rigurosos. La falta de criterios comunes a la hora de recoger o notificar los casos hace difícil una recogida veraz y uniforme. Es necesaria la comunicación de cualquier incidente relacionado con las prótesis mamarias, tanto a los registros nacionales de implantes como a la comunidad científica, a fin de recopilar información de calidad como base para latoma de decisiones basadas en evidencia


BACKGROUND AND OBJECTIVE: In 1995, the first notification relating anaplastic large cell lymphoma (BIA-ALCL) and breast implants was established. Twenty four years later, hundreds of articles have been published about this topic. The aim of this study is to review the published cases and summarize the current knowledge about this entity bringing it closer to Hispanic readers. METHODS: A systematic review was performed in PubMed, ScienceDirect, SciELO and Google Scholar databases since 1995 to October 2019. RESULTS: A total number of 122 case reports were analyzed. The information collected was heterogeneous. The shortage of Ibero-Latinoamerican published cases was evidenced. Data elements abstracted included information about patient demographics, medical history, implant characteristics, presenting symptoms, diagnosis and staging, treatment, and patient outcomes. CONCLUSIONS: Despite diagnosis and current treatment to BIA-ALCL are fairly standardized, more rigorous studies are required to establish actual incidence and etiology. The lack of common criteria when collecting or reporting clinical cases makes difficult a truthful and uniform data collection. Communication of any incident related to breast implants, both to the national implant registries and to the scientific community, is necessary in order to gather quality information as a basis for evidence-based decision making


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Linfoma Anaplásico de Células Grandes/diagnóstico , Linfoma Anaplásico de Células Grandes/etiologia , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/etiologia , Implante Mamário/efeitos adversos , Imuno-Histoquímica , Biópsia
13.
Cancer Causes Control ; 31(5): 403-416, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32130573

RESUMO

PURPOSE: The risk of being diagnosed with contralateral breast cancer (CBC) is an important health issue among breast cancer survivors. There is an increasing interest in the effect of lifestyle and reproductive factors on CBC risk, since these factors may partly be modifiable. We performed a systematic review and meta-analysis and aimed to evaluate the impact of lifestyle and reproductive factors on CBC risk in population-based breast cancer studies. METHODS: The PubMed electronic database was searched up to 2nd November 2019, for relevant publications. Of the included studies, a meta-analysis per lifestyle or reproductive factor was performed. RESULTS: Thirteen out of 784 publications were used for the meta-analysis. Body mass index (≥ 25 vs. < 25 kg/m2; RR = 1.22; 95% CI 1.01-1.47) was associated with increased CBC risk. The estimates for alcohol use (ever vs. never; RR = 1.15; 95% CI 1.02-1.31) and age at primiparity (≥ 25 vs. < 25 years; RR = 1.06; 95% CI 1.02-1.10) also showed an association with increased CBC risk. For parity (≥ 4 vs. nulliparous; RR = 0.56; 95% CI 0.42-0.76) and age at menopause (< 45 vs ≥ 45 years; RR = 0.79; 95% CI 0.67-0.93), results from two studies suggested a decreased CBC risk. We observed no association between CBC and smoking, age at menarche, oral contraceptive use, gravidity, breastfeeding, or menopausal status. Overall, the number of studies per risk factor was limited (n = 2-5). CONCLUSIONS: BMI is a modifiable risk factor for CBC. Data on the effect of other modifiable lifestyle and reproductive factors are limited. For better counseling of patients on lifestyle effects, more studies are urgently needed.


Assuntos
Neoplasias da Mama/etiologia , Estilo de Vida , Segunda Neoplasia Primária/etiologia , Adulto , Índice de Massa Corporal , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Paridade , Gravidez , História Reprodutiva , Fatores de Risco , Adulto Jovem
14.
Medicine (Baltimore) ; 99(9): e19383, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32118786

RESUMO

RATIONALE: Breast metastasis from serous borderline tumor with micro-invasive carcinoma of ovary is a very rare condition. The breast lump as the only clinical presentation is rarely seen in ovarian carcinoma, which may lead to be misdiagnosed, and the mechanism of breast metastasis from ovarian tumors in early stage still needs to be explored. Differentiation from primary breast cancer and extramammary malignancy is crucial because the treatment and prognosis are significantly different. PATIENT CONCERNS: A 33-year-old female presented with a painless, movable, 1.0 × 1.0 cm lump in the upper outer quadrant of the right breast for a month. DIAGNOSES: Breast metastasis of serous borderline tumor with micro-invasive ovarian carcinoma confirmed by pathology and immunohistochemistry. INTERVENTIONS: The patient underwent lumpectomy, bilateral ovarian tumor stripping operation and prophylactic chemotherapy. OUTCOMES: No signs of recurrence have been detected in 1.5 years of follow-up. LESSONS: Distant metastasis may occur in early stage of ovarian carcinoma. It is important to determine the origin of the primary tumor and develop an effective treatment strategy for patients. Imaging findings and pathological diagnostic criteria are important to accurately differentiate between metastasis and primary breast lesions, which may improve the patient's outcomes.


Assuntos
Neoplasias da Mama/diagnóstico , Metástase Neoplásica/diagnóstico , Neoplasias Ovarianas/complicações , Adulto , Neoplasias da Mama/etiologia , Neoplasias da Mama/fisiopatologia , Cistadenocarcinoma Seroso/diagnóstico , Cistadenocarcinoma Seroso/etiologia , Cistadenocarcinoma Seroso/patologia , Feminino , Humanos , Metástase Neoplásica/patologia , Neoplasias Ovarianas/fisiopatologia , Ultrassonografia/métodos
15.
Med. leg. Costa Rica ; 37(1): 93-100, ene.-mar. 2020.
Artigo em Espanhol | LILACS | ID: biblio-1098376

RESUMO

Resumen El cáncer de mama es uno de los tipos más frecuentes de cáncer en la población femenina y presenta una estrecha relación con la herencia genética. El asesoramiento genético procura informar y guiar a las pacientes durante todo el proceso de identificación y diagnóstico de cáncer de mama hereditario. Por lo que con el presente artículo se pretende demostrar la relevancia del asesoramiento genético en el abordaje de las pacientes con cáncer de mama hereditario. Se realizó una revisión sistemática de la literatura para la selección de publicaciones científicas que aporten conocimiento sobre el cáncer de mama en relación con la herencia genética y otros documentos que demuestren la importancia del asesoramiento genético en pacientes con cáncer de mama hereditario. Con esta revisión, se obtuvo información valiosa sobre la importancia de la implementación del asesoramiento genético, durante la realización de pruebas genéticas, en pacientes con cáncer de mama hereditario.


Abstract Breast cancer is one of the most frequent types of cancer in the female population and has a close relationship with genetic inheritance. Genetic counseling seeks to inform and guide patients throughout the process of identification and diagnosis of hereditary breast cancer. Therefore, this article intends to demonstrate the relevance of genetic counseling in the approach of patients with hereditary breast cancer. It has been made a systematic review of the literature for the selection of scientific publications that provide knowledge about breast cancer in relation to genetic inheritance and other documents demonstrating the importance of genetic counseling in patients with hereditary breast cancer was performed. With this review, valuable information was obtained on the importance of the implementation of genetic counseling, during genetic testing, in patients with hereditary breast cancer.


Assuntos
Humanos , Feminino , Neoplasias da Mama/etiologia , Neoplasias da Mama/genética , Testes Genéticos/métodos , Costa Rica , Aconselhamento Genético
16.
Sci Adv ; 6(4): eaaw6938, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-32010778

RESUMO

A central goal of precision medicine is to predict disease outcomes and design treatments based on multidimensional information from afflicted cells and tissues. Cell morphology is an emergent readout of the molecular underpinnings of a cell's functions and, thus, can be used as a method to define the functional state of an individual cell. We measured 216 features derived from cell and nucleus morphology for more than 30,000 breast cancer cells. We find that single cell-derived clones (SCCs) established from the same parental cells exhibit distinct and heritable morphological traits associated with genomic (ploidy) and transcriptomic phenotypes. Using unsupervised clustering analysis, we find that the morphological classes of SCCs predict distinct tumorigenic and metastatic potentials in vivo using multiple mouse models of breast cancer. These findings lay the groundwork for using quantitative morpho-profiling in vitro as a potentially convenient and economical method for phenotyping function in cancer in vivo.


Assuntos
Neoplasias da Mama/patologia , Análise de Célula Única , Animais , Biomarcadores Tumorais , Neoplasias da Mama/etiologia , Linhagem Celular Tumoral , Progressão da Doença , Feminino , Perfilação da Expressão Gênica , Humanos , Camundongos , Metástase Neoplásica , Estadiamento de Neoplasias , Fenótipo , Prognóstico , Análise de Célula Única/métodos , Transcriptoma
17.
Eur J Epidemiol ; 35(6): 579-589, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32026169

RESUMO

Experimental and epidemiologic studies suggest that light at night (LAN) exposure disrupts circadian rhythm, and this disruption may increase breast cancer risk. We investigated the potential association between residential outdoor LAN and breast cancer risk. A population-based case-control study was conducted in Vancouver, British Columbia and Kingston, Ontario, Canada with incident breast cancer cases, and controls frequency matched by age in the same region. This analysis was restricted to 844 cases and 905 controls who provided lifetime residential histories. Using time-weighted average duration at each home 5-20 years prior to study entry, two measures of cumulative average outdoor LAN were calculated using two satellite data sources. Logistic regression was used to estimate the relationship between outdoor LAN and breast cancer risk, considering interactions for menopausal status and night shift work. We found no association between residential outdoor LAN and breast cancer for either measure of LAN [OR comparing highest vs. lowest tertile (DNB) = 0.95, 95% CI 0.70-1.27]. We also found no association when considering interactions for menopausal status and past/current night work status. These findings were robust to changes to years of residential data considered, residential mobility, and longer exposure windows. Our findings are consistent with studies reporting that outdoor LAN has a small effect or no effect on breast cancer risk.


Assuntos
Neoplasias da Mama/epidemiologia , Ritmo Circadiano/fisiologia , Luz , Tolerância ao Trabalho Programado/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/etiologia , Colúmbia Britânica/epidemiologia , Feminino , Humanos , Incidência , Pessoa de Meia-Idade , Ontário/epidemiologia , Vigilância da População , Receptores Estrogênicos/metabolismo , Receptores de Progesterona/metabolismo , Características de Residência , Saúde da Mulher
18.
BMC Cancer ; 20(1): 78, 2020 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-32000718

RESUMO

BACKGROUND: Although immediate breast reconstruction has been reported to be oncologically safe, no affirmative study comparing the two reconstruction methods exists. We investigated breast cancer recurrence rates in two breast reconstruction types; implant reconstruction and autologous flap reconstruction. METHODS: A retrospective cohort study was performed on propensity score-matched (for age, stage, estrogen receptor status) patients who underwent IBR after mastectomy at Seoul National University Hospital between 2010 and 2014. The main outcomes determined were locoregional recurrence-free interval (LRRFI) and disease-free interval (DFI). RESULTS: We analyzed 496 patients among 731 patients following propensity score matching (Median age 43, 247 implant reconstruction and 249 flap reconstruction). During median follow-up of 58.2 months, DFI was not different between the two groups at each tumor stage. However, flap reconstruction showed inferior DFI compared to implant reconstruction in patients with high histologic grade (p = 0.012), and with high Ki-67 (p = 0.028). Flap reconstruction was related to short DFI in multivariate analysis in aggressive tumor subsets. Short DFI after flap reconstruction in aggressive tumor cell phenotype was most evident in hormone positive/Her-2 negative cancer (p = 0.008). LRRFI, on the other hand, did not show difference according to reconstruction method regardless of tumor cell aggressiveness. CONCLUSION: Although there is no difference in cancer recurrence according to reconstruction method in general, flap-based reconstruction showed higher systemic recurrence associated with histologically aggressive tumors.


Assuntos
Neoplasias da Mama/mortalidade , Neoplasias da Mama/cirurgia , Mamoplastia , Mastectomia , Adulto , Implantes de Mama , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/etiologia , Terapia Combinada , Feminino , Humanos , Mamoplastia/efeitos adversos , Mamoplastia/métodos , Mastectomia/efeitos adversos , Mastectomia/métodos , Pessoa de Meia-Idade , Pontuação de Propensão , Modelos de Riscos Proporcionais , Recidiva , Retalhos Cirúrgicos , Resultado do Tratamento
19.
Future Oncol ; 16(8): 395-412, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32026709

RESUMO

Multiple synchronous (multifocal or multicentric) ipsilateral breast cancers with heterogeneous histopathology are a rare clinical occurrence, however, their incidence is increasing due to the use of MRI for breast cancer screening and staging. Some studies have demonstrated poorer clinical outcomes for this pattern of breast cancer, but there is no evidence to guide clinical practice. In this multidisciplinary review, we reflect on pathology and molecular characteristics, imaging findings, surgical management including conservation and reconstructive options and approach to the axilla, and the role of chemotherapy and radiotherapy. Multidisciplinary discussions appear decisive in planning an appropriate surgical choice and defining the correct systemic treatment tailored to each clinical condition.


Assuntos
Neoplasias da Mama/diagnóstico , Carga Tumoral , Neoplasias da Mama/etiologia , Neoplasias da Mama/mortalidade , Neoplasias da Mama/terapia , Terapia Combinada , Gerenciamento Clínico , Suscetibilidade a Doenças , Feminino , Predisposição Genética para Doença , Humanos , Linfocintigrafia , Imagem Multimodal/métodos , Gradação de Tumores , Estadiamento de Neoplasias , Prognóstico , Retratamento , Biópsia de Linfonodo Sentinela , Resultado do Tratamento
20.
Sci Adv ; 6(4): eaay9819, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-32010791

RESUMO

Disassembly of intercellular junctions is a hallmark of epithelial-mesenchymal transition (EMT). However, how the junctions disassemble remains largely unknown. Here, we report that E3 ubiquitin ligase Smurf1 targets p120-catenin, a core component of adherens junction (AJ) complex, for monoubiquitination during transforming growth factor ß (TGFß)-induced EMT, thereby leading to AJ dissociation. Upon TGFß treatment, activated extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylates T900 of p120-catenin to promote its interaction with Smurf1 and subsequent monoubiquitination. Inhibition of T900 phosphorylation or ubiquitination of p120-catenin abrogates TGFß-induced AJ dissociation and consequent tight junction (TJ) dissociation and cytoskeleton rearrangement, hence markedly blocking lung metastasis of murine breast cancer. Moreover, the T900 phosphorylation level of p120-catenin is positively correlated with malignancy of human breast cancer. Hence, our study reveals the underlying mechanism by which TGFß induces dissociation of AJs during EMT and provides a potential strategy to block tumor metastasis.


Assuntos
Cateninas/metabolismo , Transição Epitelial-Mesenquimal , Neoplasias/metabolismo , Fator de Crescimento Transformador beta/metabolismo , Junções Aderentes , Animais , Neoplasias da Mama/etiologia , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Células Cultivadas , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Feminino , Humanos , Camundongos , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Neoplasias/etiologia , Neoplasias/patologia , Fosforilação , Fator de Crescimento Transformador beta/farmacologia , Ubiquitina-Proteína Ligases/metabolismo , Ubiquitinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA